Read by QxMD icon Read

Lung cancer,meta-analysis

Edith Lahner, Marina Capasso, Marilia Carabotti, Bruno Annibale
BACKGROUND: Pernicious anaemia (PA) is associated with increased gastric cancer risk, but the evidence is conflicting regarding the associated risk of other cancers. AIM: To systematically determine the incidence rates of gastro-intestinal cancers other than gastric cancers (GI-other-than-GC) and non-gastrointestinal cancers (non-GIC) in PA adults, globally and per tumour site, and the risk associated with PA for GI-other than GC and non-GIC. METHODS: Studies of PA patients reporting the incidence of GI-other-than-GCs and non-GICs were identified with MEDLINE (PubMed)-EMBASE (from first date available to April 2017)...
May 24, 2018: Digestive and Liver Disease
Jungho Yang, Jung-Soo Pyo, Guhyun Kang
PURPOSE: The aim of this study was to investigate the rate of ROS1 rearrangement and concordance between ROS1 immunohistochemistry (IHC) and molecular tests in non-small cell lung cancer (NSCLC). METHODS: The study included 10,898 NSCLC cases from 21 eligible studies. ROS1 rearrangement rates were evaluated in NSCLC by a meta-analysis, including subgroup analyses. In addition, we performed a concordance analysis and a diagnostic test accuracy review of ROS1 IHC in NSCLC...
June 1, 2018: International Journal of Biological Markers
Ross A Soo, Zhaojin Chen, Rebecca Siew Yan Teng, Hon-Lyn Tan, Barry Iacopetta, Bee Choo Tai, Richie Soong
Background: Tumor-associated immune cells are prognostic in non-small cell lung cancer (NSCLC) but findings have been conflicting. Objectives: To determine the prognostic role of immune cells according to localization in NSCLC patients. Methods: A systematic literature review and meta-analysis was performed on dendritic cell (DC), tumor associated macrophages (TAM), mast cells (MC), natural killer (NK) cells, T and B cells and tumor CTLA-4 and PD-L1 studies...
May 15, 2018: Oncotarget
Cho-Hao Lee, Chin Lin, Chieh-Yung Wang, Tzu-Chuan Huang, Yi-Ying Wu, Wu-Chien Chien, Jia-Hong Chen
Numerous evidence has indicated that excess weight is associated with an increased risk of mortality in patients in several cancer types including breast, colorectal, pancreatic, endometrial, and prostate cancer However, with respect to non-small cell lung cancer and upper aero-digestive cancer, evidence suggests that low body mass index (BMI) may increase the risk of mortality of these cancers, but a definitive link between premorbid BMI and overall survival in small cell lung cancer patients has yet to be fully explored...
May 15, 2018: Oncotarget
Hongjun Zhu, Shuanglin Zhang
BACKGROUND: Obesity is found to increase the risk of most cancer types, but reduce lung cancer risk in many studies. However, the association between obesity and lung cancer is still controversial, mainly owing to the confounding effect of smoking. METHODS: Eligible studies were identified from electric databases to July 1, 2017. Relevant data were extracted and pooled using random-effects models; dose-response and subgroup analyses were also performed. RESULTS: Twenty-nine studies with more than 10,000 lung cancer cases in15 million never smokers were included...
June 5, 2018: BMC Cancer
Chengzhi Huang, Mengya Yu, Xueqing Yao
OBJECTIVE: Although the role of microRNA-17 (miR-17) has been identified as a tumour biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyse and summarise the relationship between the miR-17 status and clinical outcome in a variety of human cancers. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science and Embase from the first year of records to 15 May 2017...
May 31, 2018: BMJ Open
Pedro N Aguiar, Benjamin Haaland, Wungki Park, Pui San Tan, Auro Del Giglio, Gilberto de Lima Lopes
Importance: The survival of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and erlotinib for treatment-naive patients...
May 31, 2018: JAMA Oncology
Shaodong Tong, Zhaohui Qin, Minghui Wan, Longzhen Zhang, Yan Cui, Yuanhu Yao
Background: Non-small cell lung cancer (NSCLC) accounts for 85% to 90% of lung cancer cases. At diagnosis, around 30% of NSCLC patients are already at stage IIIA (N2). One standard treatment for this stage is induction chemotherapy followed by surgery, whether induction chemoradiotherapy is superior to induction chemotherapy remains uncertain. We therefore performed a systematic review and meta-analysis of published randomized control trials to evaluate the therapeutic efficacy and toxicity of induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) NSCLC...
April 2018: Journal of Thoracic Disease
Hengrui Liang, Zhenkui Pan, Wei Wang, Chengye Guo, Difei Chen, Jianrong Zhang, Yiyin Zhang, Shiyan Tang, Jianxing He, Wenhua Liang
Background: Treatment-naive epidermal growth factor receptor (EGFR) T790M mutation is more inclined to coexist with L858R than with 19 del in non-small cell lung cancer (NSCLC) patients. However, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) might alter this status. We sought to compare the prevalence of T790M upon acquired resistance to EGFR-TKIs between 19 del and L858R by assembling all existing data. Methods: Electronic databases were comprehensively searched for eligible studies...
April 2018: Journal of Thoracic Disease
Xinyu Yang, Ming Li, Xiaodong Yang, Mengnan Zhao, Yiwei Huang, Xiyu Dai, Tian Jiang, Mingxiang Feng, Cheng Zhan, Qun Wang
Background: Uniport video-assisted thoracoscopic surgery (VATS) has emerged as a less invasive approach for the treatment of non-small cell lung cancer (NSCLC). However, whether uniport VATS has more potential advantages over multiport VATS remains controversial. This meta-analysis aimed to compare the perioperative efficacy of uniport and multiport VATS for T1-3N0M0 NSCLC. Methods: An electronic and manual search of literature published before 1st October 2017 was conducted using PubMed, Embase, Web of Science, and the Wiley Online library...
April 2018: Journal of Thoracic Disease
Kwan-Il Kim, Ji Hee Jun, Hyunjung Baek, Jae-Hyo Kim, Beom-Joon Lee, Hee-Jae Jung
BACKGROUND: Radiation pneumonitis is a common and serious complication of radiotherapy. Many published randomized controlled studies (RCTs) reveal a growing trend of using herbal medicines as adjuvant therapy to prevent radiation pneumonitis; however, their efficacy and safety remain unexplored. OBJECTIVE: The aim of this systematic review is to evaluate the efficacy and safety of herbal medicines as adjunctive therapy for the prevention of radiation pneumonitis in patients with lung cancer who undergo radiotherapy...
2018: PloS One
Zhanwei Wang, Dionyssios Katsaros, Nicoletta Biglia, Yi Shen, Yuanyuan Fu, Lenora W M Loo, Wei Jia, Yuki Obata, Herbert Yu
PURPOSE: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been identified as a prognostic marker for the metastasis of early-stage non-small cell lung cancer (NSCLCs). We studied MALAT1 expression in breast cancer in relation to disease features and patient survival. METHODS: Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to measure MALAT1 expression in tumor samples of 509 breast cancer patients. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association between MALAT1 expression and breast cancer survival using the Cox proportional hazards regression model, and the analysis was adjusted for age at surgery, tumor grade, disease stage, and hormone receptor status...
May 29, 2018: Breast Cancer Research and Treatment
Lijun Gu, Zhiyan Wang, Jing Zuo, Hongmei Li, Lin Zha
Nuclear factor kappa B (NF-κB), a key nuclear transcription factor, is associated with prognosis in a variety of human cancers. However, the clinical value of NF-κB in non-small cell lung cancer (NSCLC) is still controversial. Therefore, the aim of this meta-analysis was to obtain an accurate evaluation of the relationship between NF-κB expression and survival prognosis of NSCLC patients based on published articles. PubMed, EMBASE and Web of Science databases were systematically searched for potential articles...
2018: PloS One
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim
The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, the prognostic impact of MET gene copy number gain (CNG) has not been consistent among studies. We performed this meta-analysis to evaluate the prognostic value of high MET CNG in patients with NSCLC. A systematic computerized search of the electronic databases including PubMed, EMBASE, Google scholar, and Cochrane Library (up to November 2017) was carried out. From twenty-one studies, 7,647 patients were included in the pooled analysis of hazard ratios (HRs) with 95% confidence intervals (CIs) for disease-free survival or overall survival...
2018: Journal of Cancer
Yun Deng, Rongquan He, Rui Zhang, Binliang Gan, Yu Zhang, Gang Chen, Xiaohua Hu
Previous studies have investigated the association between HOXA13 and non-small cell lung cancer. However, the role of HOXA13 expression in the occurrence and progression of lung adenocarcinoma (LUAD) has not yet been investigated. In the present study, HOXA13-related data mining of The Cancer Genome Atlas (TCGA), polymerase chain reaction (PCR) data from our cases and the case information in Oncomine was conducted for validation. The expression data of HOXA13 in lung cancer cell lines were also collected from the Cancer Cell Line Encyclopedia (CCLE) database for further verification...
June 2018: Oncology Letters
Cui-Min Zhu, Xiang-Yao Lian, Ying-Hui Bi, Chan-Chan Hu, Yun-Wei Liang, Qing-Shan Li
BACKGROUND: Ribonucleotide reductase subunit 1 (RRM1) is a potential prognostic factor for non-small cell lung cancer (NSCLC). This study evaluates prognostic value of RRM1 in NSCLC patients by meta-analyzing outcomes reported in literature. METHOD: Data were acquired from research articles retrieved after literature search in online databases. Random effects meta-analyses were conducted by pooling hazard ratios (HR). Meta-analyses of standardized mean differences (SMD) were used to evaluate overall survival (OS) and progression-free survival (PFS) between low and high RRM1 expression groups...
May 24, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Tara Pereiro Brea, Alberto Ruano Raviña, José Martín Carreira Villamor, Antonio Golpe Gómez, Anxo Martínez de Alegría, Luís Valdés
INTRODUCTION: The aim of this study is to assess the diagnostic value of the magnetic resonance imaging (MRI) in differentiating metastasic from non-metastatic lymph nodes in NSCLC patients compared with computed tomography (CT) and fluorodeoxyglucose (FDG) - positron emission tomography (PET) or both combined. METHODS: Twenty-three studies (19 studies and 4 meta-analysis) with sample size ranging between 22 and 250 patients were included in this analysis. MRI, regardless of the sequence obtained, where used for the evaluation of N-staging of NSCLC...
May 23, 2018: Archivos de Bronconeumología
Xin Huang, Weiyue Zhang, Zengwu Shao
Several studies have suggested that long non-coding RNA (lncRNA) gene polymorphisms are associated with cancer risk. In the present study, we conducted a meta-analysis related to studies on the association between lncRNA single-nucleotide polymorphisms (SNPs) and the overall risk of cancer. A total 12 SNPs in five common lncRNA genes were finally included in the meta-analysis. In the lncRNA antisense noncoding RNA in the INK4 locus (ANRIL), the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms, but not rs1333045 C/T, were correlated with overall cancer risk...
May 25, 2018: Bioscience Reports
Jonathan Graham, Stephanie Earnshaw, Kate Burslem, Jonathan Lim
BACKGROUND: Afatinib is 1 of 3 tyrosine kinase inhibitors approved in the United States for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations. In clinical trials, afatinib has demonstrated improvement in progression-free survival versus standard chemotherapy and gefitinib. OBJECTIVE: To analyze the impact of increases in afatinib treatment share on the cost and health outcomes in a commercial health plan in the United States...
June 2018: Journal of Managed Care & Specialty Pharmacy
Lu Wang, Mingtao Huang, Hui Ding, Guangfu Jin, Liang Chen, Feng Chen, Hongbing Shen
The association between adult height and risk of lung cancer has been investigated by epidemiology studies, but the results are inconsistent. Mendelian randomization (MR) analyses with individual-level data from two genome-wide association studies, including a total of 7127 lung cancer cases and 6818 controls, were carried out to explore whether adult height is causally associated with risk of lung cancer. A weighted genetic risk score (wGRS) was created based on genotypes of 101 known height-associated genetic variants...
May 23, 2018: Cancer Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"